MINI REVIEW article
Front. Nutr.
Sec. Nutrition and Metabolism
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1663096
This article is part of the Research TopicFunctional Foods for Metabolic HealthView all 24 articles
Advances in Traditional Chinese Medicine for the Treatment of Hyperuricemia and Associated Diseases: Pathogenesis, Mechanisms, and Future Directions
Provisionally accepted
Minghui Bi1,2*
zhuo huang2- 1Beijing University of Chinese Medicine, Xiamen Hospital, Xiamen, China
- 2Xiamen Hospital of Traditional Chinese Medicine, xiamen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hyperuricemia (HUA), characterized by elevated serum uric acid levels (>420 μmol/L), is a metabolic disorder linked to gout, cardiovascular diseases, renal disorders, diabetes, polycystic ovary syndrome (PCOS), and non-alcoholic fatty liver disease (NAFLD). Traditional Chinese Medicine (TCM) offers a holistic approach to HUA management, employing dialectical treatments to address underlying pathogenesis, reduce uric acid, mitigate inflammation, and protect organ function. This review synthesizes recent advances in TCM for HUA and its comorbidities, drawing from pharmacological studies of single herbs, compound formulas, and TCM pathogenesis theories. We introduce innovative strategies, including network pharmacology, metabolomics, personalized TCM diagnostics, and nanotechnology, to enhance therapeutic precision and efficacy. By integrating TCM's traditional wisdom —emphasizing balance among vital energies like "qi" (vital energy) and bodily fluids, with modern scientific methodologies, this review highlighting potential risks, toxicities, and challenges in TCM application, aiming to improve patient outcomes in HUA and related diseases.
Keywords: Hyperuricemia, Traditional Chinese Medicine, Gout, Cardiovascular Diseases, Renal disorders, personalized medicine, Network Pharmacology, Nanotechnology
Received: 10 Jul 2025; Accepted: 20 Aug 2025.
Copyright: © 2025 Bi and huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Minghui Bi, Beijing University of Chinese Medicine, Xiamen Hospital, Xiamen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.